Overview of Prescription Omega-3 Fatty Acid Products for Hypertriglyceridemia

@article{Weintraub2014OverviewOP,
  title={Overview of Prescription Omega-3 Fatty Acid Products for Hypertriglyceridemia},
  author={Howard S. Weintraub},
  journal={Postgraduate Medicine},
  year={2014},
  volume={126},
  pages={18 - 7}
}
  • H. Weintraub
  • Published 1 November 2014
  • Medicine
  • Postgraduate Medicine
Abstract Patients with elevated triglycerides (TG) may be at a higher risk for cardiovascular (CV) disease. Omega-3 fatty acids (OM3FAs), particularly the long-chain fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), effectively reduce TG and thus may impact CV outcomes; however, clinical data have been inconsistent. This review discusses the efficacy, safety, and key considerations of currently approved prescription OM3FA products in patients with elevated TG with or… 
The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia
TLDR
Proposed mechanisms of action of OM3FAs include inhibition of diacylglycerol acyltransferase, increased plasma lipoprotein lipase activity, decreased hepatic lipogenesis, and increased hepatic β-oxidation, which are thought to provide a better indication of cardiovascular risk in this patient population.
Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA)
The omega-3 fatty acid eicosapentaenoic acid (EPA) has multiple actions potentially conferring cardiovascular benefit, including lowering serum triglyceride (TG) and non-high-density lipoprotein
Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association.
TLDR
The use of n-3 FA (4 g/d) for improving atherosclerotic cardiovascular disease risk in patients with hypertriglyceridemia is supported by a 25% reduction in major adverse cardiovascular events in REDUCE-IT (Reduction of Cardiovascular Events With EPA Intervention Trial), a randomized placebo-controlled trial of EPA-only in high-risk patients treated with a statin.
Lipid effects of switching from prescription EPA+DHA (omega-3-acid ethyl esters) to prescription EPA only (icosapent ethyl) in dyslipidemic patients
TLDR
In this real-world retrospective analysis, switching high-risk statin-treated patients from omega-3-acid ethyl esters to icosapent ethyl resulted in favorable lipid changes, consistent with randomized controlled trials and previous case series.
History and future of omega-3 fatty acids in cardiovascular disease
TLDR
The results of the ongoing prescription-strength, high-dose OM3FA interventional trials will help define the potential role of OM3FAs in addressing residual cardiovascular risk despite statin therapy.
Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides
TLDR
Switching from omega-3-acid ethyl esters containing both EPA and DHA to icosapent ethyl containing high-purity EPA resulted in beneficial and substantial changes in the lipid profile with a notable reduction of TG levels along with additional reductions in LDL-C levels in a statin-treated obese patient with persistently high TG levels.
Improving lipids with prescription icosapent ethyl after previous use of fish oil dietary supplements.
TLDR
These cases demonstrated favorable lipid effects with prescription icosapent ethyl treatment that may help optimize the care of high-risk coronary artery disease patients with statin intolerance.
Review of Cardiometabolic Effects of Prescription Omega-3 Fatty Acids
TLDR
There is persistent population-wide enthusiasm for n-3FA as a dietary supplement for its cardiometabolic benefits and there are ongoing clinical trials to assess whether the lipid/lipoprotein benefits may be extended to other at-risk populations and whether lower-dose therapy may provide background benefit for primary prevention of ASCVD.
Icosapent ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol
TLDR
Expert opinion IPE has proven to be superior to other forms of omega 3 fatty acid in reducing CVD risk in patients with elevated TG, thus preventing the increase in low-density lipoprotein cholesterol associated with DHA especially at high TG levels.
Icosapent Ethyl: A Review of Its Use in Severe Hypertriglyceridemia
TLDR
In a pivotal phase III trial, oral icosapent ethyl 4 g/day significantly decreased the placebo-corrected median TG levels by 33.1 %.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 86 REFERENCES
Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications
TLDR
Mechanistically, most evidence suggests that omega-3 fatty acids reduce the synthesis and secretion of very-low-density lipoprotein (VLDL) particles, and increase TG removal from VLDL and chylomicron particles through the upregulation of enzymes, such aslipoprotein lipase.
Potential Benefits of Icosapent Ethyl on the Lipid Profile: Case Studies
TLDR
The lipid profiles of these two patients with dyslipidemia were improved with IPE treatment, illustrating the potentially favorable effects of IPE compared with other products containing both EPA and DHA.
Omega-3 polyunsaturated fatty acids and cardiovascular diseases.
Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease.
TLDR
Evidence from epidemiological studies and RCTs will be reviewed, and recommendations reflecting the current state of knowledge will be made with regard to both fish consumption and omega-3 fatty acid (plant- and marine-derived) supplementation.
n-3 fatty acids and cardiovascular events after myocardial infarction.
TLDR
Low-dose supplementation with EPA-DHA or ALA did not significantly reduce the rate of major cardiovascular events among patients who had had a myocardial infarction and who were receiving state-of-the-art antihypertensive, antithrombotic, and lipid-modifying therapy.
Long chain omega-3 fatty acids and cardiovascular disease: a systematic review
TLDR
Marine omega-3 fatty acids are effective in preventing cardiovascular events, cardiac death and coronary events, especially in persons with high cardiovascular risk, according to the current evidence.
...
1
2
3
4
5
...